(Q38059422)

English

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

0 references

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis (English)

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

inflammatory bowel diseases

0 references

0 references

1 reference

based on heuristic

inferred from title

Adam S. Cheifetz

2

object named as

Adam S Cheifetz

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

author name string

Kavinderjit S Nanda

1

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

Alan C Moss

3

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

language of work or name

0 references

publication date

13 November 2012

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

108

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

40-7; quiz 48

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Therapeutic drug monitoring of biologics for inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Drug development in inflammatory bowel disease: the role of the FDA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

An evidence-based systematic review on medical therapies for inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Assessing response and loss of response to biological therapies in IBD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Review article: loss of response to anti-TNF treatments in Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Quantifying heterogeneity in a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Simpson's paradox and calculation of number needed to treat from meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Meta-analysis in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

6 September 2017

Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

31 August 2018

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

31 August 2018

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

31 August 2018

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

31 August 2018

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

31 August 2018

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561464

1 October 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.363

21 January 2018

Predicting the response to infliximab from trough serum levels

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.363

21 January 2018

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.363

21 January 2018

Development of a Crohn's index for survey research

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab dose intensification in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/AJG.2012.363

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38059422&oldid=2201220951"